1. Signaling Pathways
  2. TGF-beta/Smad
  3. TGF-β Receptor
  4. ALK4 Isoform

ALK4

ALK4 (ACVR1B) is a versatile receptor that has a critical role in development. In Xenopus, ALK4 activates both sides of the developmental pathway: the TGFβ-driven left side with the ligands Xnrl and derriere and the BMP-driven right side with the ligand Vgl. This activation modulates mesoderm induction and dorsoanterior/ventroposterior development during primary axis formation. In mouse models, global knockout of Alk4 is embryonic lethal due to developmental impairment of the epiblast and extraembryonic ectoderm, leading to improper gastrulation. Activation of ALK4 can occur through a multitude of ligands, such as Activins, GDFs, and Nodal. Conditional knockouts of Alk4 in various adult tissues have been generated to analyze the impact of Alk4 systemically. Activin A signaling, mediated via ALK4, has a substantial role in reproduction. Trophoblast invasion is regulated through a canonical ALK4-mediated pathway, where upregulated SNAIL induces MMP-2 expression; knockdown of ALK4 attenuated this effect.

Cat. No. Product Name Effect Purity
  • HY-10431
    SB-431542
    Inhibitor 99.89%
    SB-431542 is a TGF-β receptor kinase inhibitor (TRKI). SB-431542 has inhibitory activity for ALK4, ALK5 and ALK7 with IC50 values of 1 μM, 0.75 μM and 2 μM, respectively. SB-431542 also inhibits TGF-β-induced transcription, gene expression, apoptosis, and growth suppression. SB-431542 can be used for the research of cancer and signal transduction pathways.
  • HY-10432
    A 83-01
    Inhibitor 99.08%
    A 83-01 is a potent inhibitor of TGF-β type I receptor ALK5 kinase, type I nodal receptor ALK4 and type I nodal receptor ALK7, with IC50s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7, respectively.
  • HY-10432A
    A 83-01 sodium
    Inhibitor ≥98.0%
    A 83-01 sodium is a potent inhibitor of TGF-β type I receptor ALK5 kinase, ALK4 and ALK7, with IC50s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7, respectively.
  • HY-15897
    LDN-212854
    Inhibitor 99.70%
    LDN-212854 is a bone morphogenetic protein (BMP) inhibitor that potently inhibits ALK2 (IC50: 1.3 nM). LDN-212854 also inhibits ALK1 (IC50: 2.40 nM). LDN-212854 can be used in the research of fibrodysplasia ossificans progressive and cancers, such as hepatocellular carcinoma (HCC).
  • HY-122856
    AZ12601011
    Inhibitor 99.88%
    AZ12601011 is an orally active, selective TGFBR1 kinase inhibitor with an IC50 of 18 nM and a Kd of 2.9 nM. AZ12601011 inhibits phosphorylation of SMAD2 via selectively inhibiting ALK4, TGFBR1, and ALK7. AZ12601011 inhibits mammary tumor growth .
  • HY-10431G
    SB-431542 (GMP)
    Inhibitor
    SB-431542 (GMP) is SB-431542 (HY-10431) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SB-431542 is a TGF-β receptor kinase inhibitor (TRKI) in SMAD signaling.
  • HY-123900
    AZ12799734
    Inhibitor 98.07%
    AZ12799734 is a selective, orally active TGFBR1 kinase inhibitor with an IC50 of 47 nM. AZ12799734 is also a pan BMP and TGFβ inhibitor.
Cat. No. Product Name / Synonyms Species Source